Ifosfamide_plus_etoposide_combined_with_regional_hyperthermia_in_patients_with_locally_advanced_sarcomas:_a_phase_II_study._From_July_1986_to_July_1989,_40_patients_(92%_pretreated)_with_deep-seated,_advanced_soft_tissue_sarcomas_(STS,_25_patients),_Ewing's_sarcomas_(ES,_eight_patients),_osteosarcomas_(OS,_three_patients)_and_chondrosarcomas_(ChS,_four_patients)_were_treated_at_the_University_of_Munich_in_a_protocol_involving_regional_hyperthermia_(RHT)_combined_with_ifosfamide_plus_etoposide._A_total_of_265_RHT_treatments_(mean,_6.6_RHT_per_patient)_were_applied_including_33_pelvic,_four_extremity,_and_three_abdominal_sites._The_mean_tumor_volume_was_537_cc_(range,_50_to_2,980_cc)._For_systemic_chemotherapy,_all_patients_received_ifosfamide_(1.5_g/m2,_days_1_to_5),_etoposide_(100_mg/m2,_days_1,_3,_and_5),_and_mesna_(300_mg/m2_x_4,_days_1_to_5)_with_RHT_given_only_on_days_1_and_5_in_repeated_cycles_every_4_weeks._Acute_toxicity_consisted_primarily_of_pain_(57%)_combined_with_local_discomfort_within_the_annular_phased_array_applicator_(AA)_of_the_BSD_hyperthermia_system_(BSD_Medical_Corp,_Salt_Lake_City,_UT)._The_average_maximum_systemic_temperature_was_37.4_+/-_0.5_degrees_C,_and_there_was_no_indication_of_enhanced_bone_marrow_toxicity_due_to_the_addition_of_RHT_to_the_systemic_chemotherapy._Detailed_thermal_mapping_by_invasive_thermometry_was_performed_in_all_patients._In_38_assessable_patients,_the_overall_objective_response_rate_was_37%:_six_complete_responses_(CRs),_four_partial_responses_(PRs),_and_four_favorable_histologic_responses_(FHRs)_(95%_confidence_limits,_22%_to_54%)._Complete_responders_are_alive_and_disease-free_at_40,_35,_23,_19,_19,_and_8_months._Of_patients_with_PR_and_FHR,_two_died_from_metastatic_disease_after_4_and_17_months_and_one_died_from_other_disease_after_27_months._The_remaining_five_patients_are_stable_at_37,_25,_21,_13,_and_8_months._Eleven_patients_showed_no_change_(NC),_and_13_patients_showed_local_tumor_progression_(PD)._The_mean_observation_time_for_all_patients_was_11.6_months._The_time-averaged_temperatures_(Ts)_of_all_RHT_treatments_calculated_as_20%_(T20),_50%_(T50),_or_90%_(T90)_of_measured_tumor_sites_differed_significantly_between_responders_and_nonresponders_(T20,_P_=_.003;_T50,_P_=_.006;_and_T90,_P_=_.004;_respectively)._These_data_support_activity_for_ifosfamide-etoposide_combined_with_RHT_in_pretreated_patients_with_advanced_sarcomas.